Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES

BioNexus Gene Lab Corp. BGLC

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.4M
▼ 21.9% YoY
$-3.0M
$-1.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

In addition, through its wholly owned subsidiary MRNA Scientific, the Company conducts genomic screening and related laboratory services. On August 23, 2017, the Company acquired all of the outstanding capital stock of MRNA Scientific Sdn. Bhd. (formerly BioNexus Gene Lab Sdn. Bhd), a Malaysian corporation incorporated in Malaysia on April 7, 2015, which it then subsequently changed its name to MRNA Scientific Sdn. Bhd. (“MRNA Scientific”) on September 19, 2023. In November 2025, the Company entered into a Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform. The Company’s principal executive office is located at Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No. 5 Jalan Bangsar Utama 1, 59000 Kuala Lumpur, Malaysia. The Company, through its wholly owned subsidiary Chemrex, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region.

Written from the business description in BioNexus Gene Lab Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 14 April 2026. Every sentence was checked against that document before publication.

Growth

USD 7.4M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.4 · Net income -3.0
5M10M-2M-3M
2018202120242025
Compound annual growth
−12.1%
−8.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −8.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−40 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -39.9% · Net -40.2%
10%20%-100%-200%
201820212025
ROE
FY2025 · ROE -35.2%
10%20%-10%-20%-30%
201820212025
Three returns, three denominators.

Each USD of equity lost 35 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.9
0.2M0.4M-1.0M-2.0M
201820212025

Total assetsUSD 9.3M
EquityUSD 8.6M
CashUSD 2.5M
Current ratio10.46×

Equity funds 93% of total assets.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BGLC, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.00.00.0−0.00.0
EBITDA $B−0.0−0.0−0.0−0.00.00.0−0.00.0
Income tax $B0.0−0.0−0.0−0.0−0.0◌0.0−0.0
Net income $B−0.0−0.0−0.0−0.00.00.0−0.00.0
Free cash flow $B−0.0−0.0−0.00.00.00.0−0.0−0.0
EPS, diluted $◌−0.09−0.17◌◌0.010.000.00
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−35.2−17.8−32.2−5.110.928.1−18.61.7
Shares out B0.000.020.020.170.170.170.100.07

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 35 reconciliationsAUDITED

Reconciled in 7 of the 8 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018. 11 checks were skipped: revenue is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inWyoming
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image